Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Company Deals

Jointown Pharmaceutical Partners with Shandong DYNE to Boost Pediatric Drug Distribution

Fineline Cube Feb 24, 2025

Jointown Pharmaceutical Group Co., Ltd (SHA: 600998), China’s largest private pharmaceutical distributor, has partnered with...

Company Drug

CSPC Pharmaceutical Initiates Phase III Trial for Ammuxetine in Depression Treatment

Fineline Cube Feb 24, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the start of a Phase III clinical...

Company Medical Device

Subtle Medical Integrates DeepSeek with FDA-Approved SupMR AI Platform

Fineline Cube Feb 24, 2025

Shanghai-based Subtle Medical Inc., an AI-powered medical imaging firm operating in the U.S. and China,...

Company Deals

AWS Collaborates with MSK to Accelerate Oncology Research via AI and Cloud Tech

Fineline Cube Feb 24, 2025

Amazon Web Services (AWS) announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK),...

Company Deals

Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines

Fineline Cube Feb 24, 2025

China-based glycolipid metabolism specialist Cholesgen (Shanghai) Co. Ltd. has reportedly raised over RMB100 million ($13.8...

Company Drug

Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment

Fineline Cube Feb 24, 2025

Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...

Company Deals

Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones

Fineline Cube Feb 24, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of...

Company

Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities

Fineline Cube Feb 24, 2025

Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business...

Company Drug

Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials

Fineline Cube Feb 24, 2025

China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015,...

Company Drug

Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials

Fineline Cube Feb 24, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has...

Company Drug

Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease

Fineline Cube Feb 24, 2025

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a...

Company Deals

Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights

Fineline Cube Feb 24, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) announced on February 21, 2025, that it plans to...

Company Drug

Coherent Biopharma’s CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer

Fineline Cube Feb 24, 2025

Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), announced that the U.S....

Company Drug

Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress

Fineline Cube Feb 24, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...

Company Drug

Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy

Fineline Cube Feb 24, 2025

China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical...

Company Drug

J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction

Fineline Cube Feb 24, 2025

U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...

Company Medical Device

MicroPort CardioFlow’s AnchorMan LAA Occluder System Earns CE Mark Approval

Fineline Cube Feb 24, 2025

Hong Kong-listed MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has received the CE mark for...

Company Drug

AIM Vaccine Leverages DeepSeek AI to Optimize mRNA Shingles Vaccine Design

Fineline Cube Feb 24, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) has filed its mRNA-based shingles vaccine with the...

Company Drug

Innovent Biologics’ Ipilimumab NDA Accepted by CDE with Priority Review for Colon Cancer

Fineline Cube Feb 24, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that the Center for Drug Evaluation (CDE), National...

Policy / Regulatory

AI in Healthcare: The Impact of DeepSeek Technology and Industry Developments

Fineline Cube Feb 23, 2025

The integration of advanced AI technologies into healthcare is revolutionizing the industry, and the recent...

Posts pagination

1 … 247 248 249 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.